Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 3:15 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 577–600 of 21,483 matching trials from the live ClinicalTrials.gov search.

Filters: Boston, Massachusetts Clear all

Conditions: Clostridium Infections, Diarrhea
Interventions: PAR-101/OPT-80, Vancomycin; Drug
Lead sponsor: Optimer Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA); Industry
Eligibility: 16 Years and older
Enrollment: 535 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 53
States / cities: Gadsden, Alabama • Phoenix, Arizona • Hot Springs, Arkansas + 50 more

Conditions: Neurofibromatosis 1 (NF1), Neurofibromatosis Type I
Interventions: GentleMax Pro (with skin cooling), GentleMax Pro (without skin cooling); Device
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Intermediate Risk Prostate Cancer, High Risk Prostate Cancer, Prostate Cancer
Interventions: PSMA PET/CT, Androgen Deprivation Therapy (ADT) +/- bicalutamide, Stereotactic Body Radiation Therapy (SBRT) +/- focal microboost; Diagnostic Test · Drug · Radiation
Lead sponsor: Martin T. King, MD, PhD; Other
Eligibility: 18 Years and older · Male only
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 4
States / cities: Boston, Massachusetts • Milford, Massachusetts • Weymouth, Massachusetts

Conditions: Left Ventricular Dysfunction, Coronary Artery Disease
Interventions: Impella CP® / Impella CP® with SmartAssist® / Impella 2.5®, IABP Intra-aortic balloon pump; Device
Lead sponsor: Abiomed Inc.; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 1,252 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 83
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 65 more

Conditions: Grade II Glioma, Grade III Glioma, Grade IV Glioma, Astrocytoma, Oligodendroglioma of Brain, Anaplastic Astrocytoma of Brain, Anaplastic Oligodendroglioma, Glioblastoma
Interventions: Microdevice; Combination Product
Lead sponsor: Oliver Jonas; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2028
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Schizophrenia
Interventions: d-cycloserine; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 65 Years
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Chronic Plaque Psoriasis, Psoriasis
Interventions: M923, Humira; Biological
Lead sponsor: Momenta Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 572 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 24
States / cities: Beverly Hills, California • Encino, California • La Mesa, California + 20 more

Conditions: Small-cell Lung Cancer, Extensive Stage Small-cell Lung Cancer
Interventions: Tarlatamab, Durvalumab, Carboplatin, Etoposide; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 350 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 50
States / cities: Casa Grande, Arizona • Goodyear, Arizona • Hot Springs, Arkansas + 45 more

Conditions: Pain, Visceral Pain, Pancreatic Cancer
Interventions: Transcranial Magnetic Stimulation; Procedure
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Idiopathic Gastroparesis, Diabetic Gastroparesis, Gastroparesis
Interventions: Tradipitant, Placebo, Open Label Tradipitant; Drug
Lead sponsor: Vanda Pharmaceuticals; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 979 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 36
States / cities: Birmingham, Alabama • Peoria, Arizona • Little Rock, Arkansas + 30 more

Conditions: Cystic Fibrosis
Interventions: N91115; Drug
Lead sponsor: Nivalis Therapeutics, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015
U.S. locations: 19
States / cities: Birmingham, Alabama • Palo Alto, California • Aurora, Colorado + 15 more

Conditions: Acute Coronary Syndrome
Interventions: Intervention arm: Text Message Intervention; Behavioral
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Arnica, Third Molar Extraction
Interventions: SinEcch, Placebo; Drug · Other
Lead sponsor: Tufts University; Other
Eligibility: 18 Years to 40 Years
Enrollment: 53 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Dyspnea, Acute Decompensated Heart Failure
Interventions: Recording Doppler ultrasound signals noninvasively; Device
Lead sponsor: Echosense Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Severe Aortic Stenosis
Interventions: Medtronic CoreValve® System Transcatheter Aortic Valve Implantation (TAVI), Surgical Aortic Valve Replacement (SAVR); Device
Lead sponsor: Medtronic Cardiovascular; Industry
Eligibility: Not listed
Enrollment: 1,453 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2019
U.S. locations: 45
States / cities: Phoenix, Arizona • Los Angeles, California • Mountain View, California + 35 more

Conditions: Macular Telangiectasia Type 2 (MacTel)
Interventions: NT-501/revakinagene taroretcel-lwey; Combination Product
Lead sponsor: Neurotech Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 234 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 23
States / cities: La Jolla, California • Los Angeles, California • Palo Alto, California + 19 more

Conditions: Caries, Dental
Interventions: 10% w/v chlorhexidine acetate coating FDA IND #45466, Placebo; Drug · Other
Lead sponsor: Tufts University; Other
Eligibility: 18 Years and older
Enrollment: 983 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 4
States / cities: Tuba City, Arizona • Boston, Massachusetts • Portland, Oregon

Conditions: Venous Leg Ulcer
Interventions: EscharEx (5% EX-02 formulation), Gel Vehicle, Non-surgical standard of care (NSSOC); Drug
Lead sponsor: MediWound Ltd; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 21
States / cities: Carlsbad, California • Fresno, California • Los Angeles, California + 17 more

Conditions: Breast Cancer
Interventions: high performance liquid chromatography, laboratory biomarker analysis, spectroscopy; Other · Procedure
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: Up to 120 Years · Female only
Enrollment: 1,500 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2025
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Alopecia Areata
Interventions: PF-06651600 Induction Dose, PF-06651600 Maintenance Dose #1, PF-06651600 Maintenance Dose #2, PF-06651600 Maintenance Dose #3, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 12 Years and older
Enrollment: 718 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 46
States / cities: Birmingham, Alabama • Beverly Hills, California • Irvine, California + 25 more

Conditions: Prostate Adenocarcinoma, Stage I Prostate Cancer, Stage IIA Prostate Cancer, Stage IIB Prostate Cancer, Stage III Prostate Cancer
Interventions: Bicalutamide, Goserelin Acetate, Laboratory Biomarker Analysis, Leuprolide Acetate, Therapeutic Conventional Surgery, Vorinostat; Drug · Other · Procedure
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 19 Years and older · Male only
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 15
States / cities: Los Angeles, California • San Francisco, California • Chicago, Illinois + 12 more

Conditions: Cervical Cancer
Interventions: GSK1120212 (trametinib), GSK2141795; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older · Female only
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Organ Transplantation
Interventions: everolimus (RAD); Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 68
States / cities: Birmingham, Alabama • Mobile, Alabama • Los Angeles, California + 51 more

Conditions: COVID-19
Interventions: Lopinavir/Ritonavir 400 mg/100 mg, Placebo; Drug · Other
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 452 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 6
States / cities: Aurora, Colorado • Boston, Massachusetts • Jackson, Mississippi + 3 more

Search by objective public record fields.

PAR-101/OPT-80 Versus Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD)

Assessing the Efficacy of Repeat, Monthly Treatments of Alexandrite Laser for NF1-associated Cutaneous Neurofibromas (cNFs)

Androgen-responsive POSLUMA-guided Intra-prostatic Boost

Impella®-Supported PCI in High-Risk Patients With Complex Coronary Artery Disease and Reduced Left Ventricular Function

Implantable Microdevice In Primary Brain Tumors

Effects of Weekly Dosing of D-cycloserine on Cognitive Function in Individuals With Schizophrenia

Phase 3 Study of M923 and Humira® in Subjects With Chronic Plaque-type Psoriasis

A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)

TMS for the Treatment of Pancreatic Cancer Pain

Evaluating the Safety and Efficacy of Tradipitant vs. Placebo in Idiopathic and Diabetic Gastroparesis

Study of N91115 in Patients With Cystic Fibrosis Homozygous F508del-CFTR Mutation

Piloting Text Messages to Promote Positive Affect and Physical Activity

Efficacy of Arnica Montana in Reducing Postoperative Edema and Pain

Evaluation of Cardiopulmonary Diseases by Ultrasound

Safety and Efficacy Study of the Medtronic CoreValve® System in the Treatment of Symptomatic Severe Aortic Stenosis in High Risk and Very High Risk Subjects Who Need Aortic Valve Replacement

Phase 4 Study: Long-term Safety and Efficacy of NT-501 in MacTel Type 2, Including Sham Procedure Participants

Prevention of Adult Caries Study (PACS)

A Study to Evaluate the Safety and the Efficacy of EscharEx (EX-02 Formulation) in Debridement of Venous Leg Ulcers

Nutrition-Related Biomarkers in Predicting Breast Cancer Risk in Women

PF-06651600 for the Treatment of Alopecia Areata

Androgen Deprivation Therapy and Vorinostat Followed by Radical Prostatectomy in Treating Patients With Localized Prostate Cancer

GSK1120212+GSK2141795 for Cervical Cancer

A Facilitated Access Program to Provide Everolimus (RAD) Maintenance for Patients Completing Therapy in RAD Trials in Solid Organ Transplantation

Trial of Early Therapies During Non-hospitalized Outpatient Window for COVID-19